abstract |
The present invention provides an anti-IL-17 aptamer having improved in-vivo stability, said aptamer comprising a compound represented by formula (I) (wherein the symbols are as defined in the description) or a pharmaceutically acceptable salt thereof, and a solvate or hydrate. |